High-risk groups priority for latest adapted Covid-19 vaccines: ECDC

The European Centre for Disease Prevention and Control said that individuals in high-risk groups and healthcare workers should be prioritised when the latest adapted Covid-19 vaccines are rolled out.

Coronavirus vaccines, booster shot
Photo: Bloomberg
IANS Stockholm
2 min read Last Updated : Sep 07 2022 | 2:22 PM IST

The European Centre for Disease Prevention and Control (ECDC) said that individuals in high-risk groups and healthcare workers should be prioritised when the latest adapted Covid-19 vaccines are rolled out across the continent before autumn.

These steps should be taken to prevent healthcare systems from becoming overburdened, the ECDC emphasized.

According to the health body, Comirnaty Original/Omicron BA.1 and Spikevax Bivalent Original/Omicron BA.1 have recently been authorized for use in the European Union by the European Medicines Agency, reports Xinhua news agency.

Both provide better protection against the Omicron BA.1 variant and other lineages than the vaccines currently in use, it said.

"With the newly authorized adapted Cocid-19 vaccines, member states will now have a wider range of choices to roll out autumn/winter Covid-19 immunization campaigns aimed at protecting the most vulnerable groups, and boost their immunity against the most recent emerging variants," said ECDC Director Andrea Ammon.

The new vaccines have been approved for use as booster doses for individuals aged 12 and older.

However, people over 60, those with underlying medical conditions and pregnant women, residents and staff in long-term care facilities should be first in line, ECDC said.

Meanwhile, healthcare workers should also be prioritized for additional booster doses.

"Timely vaccination and deployment of boosters ahead of a potential autumn and winter surge of Covid-19 cases is essential for protecting people and stopping health systems from being overwhelmed," ECDC said.

The vaccines that are currently in use still play an important role, Ammon said.

"As these new vaccines are currently approved for use as booster doses only, the original ones remain essential to increase the vaccination coverage," she said.

--IANS

ksk/

 

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus Vaccine

First Published: Sep 07 2022 | 2:22 PM IST

Next Story